| Identification | Back Directory | [Name]
4H-[1]Benzopyrano[3,4-d]isoxazole, 7-(1,1-dimethylheptyl)-9-methoxy-4,4-dimethyl- | [CAS]
1949726-13-9 | [Synonyms]
PM 226
PM226,PM-226
4H-[1]Benzopyrano[3,4-d]isoxazole, 7-(1,1-dimethylheptyl)-9-methoxy-4,4-dimethyl- | [Molecular Formula]
C22H31NO3 | [MDL Number]
MFCD34470349 | [MOL File]
1949726-13-9.mol | [Molecular Weight]
357.49 |
| Chemical Properties | Back Directory | [Boiling point ]
482.7±45.0 °C(Predicted) | [density ]
1.036±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
-2.88±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
PM226 is a selective cannabinoid CB2R agonist (Ki (CB2R)=13 nM; EC50 (CB2R)=39 nM; Ki (CB1R) >40 μM;) with neuroprotective properties in vitro and vivo[1]. | [in vivo]
PM226 (0.1, 1 and 10 mg/kg; administered i.p.) administration decreases the volume of the striatal lesion caused by Malonate[2]. | Animal Model: | Malonate-lesioned adult (12 week old; 350-400 g) male Wistar rats[2] | | Dosage: | 0.1, 1 and 10 mg/kg | | Administration: | Administered i.p. | | Result: | Reduced the volume of edema observed in Malonate-lesioned rats at the dose of 1 mg/kg. |
| [IC 50]
CB2: 13 nM (Ki); CB2: 39 nM (EC50) | [References]
[1] Gemma Navarro, et al. Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Front Neurosci. 2016 Sep 13;10:406. DOI:10.3389/fnins.2016.00406
[2] M Gómez-Ca?as, et al. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-215. DOI:10.1016/j.phrs.2016.03.021 |
|
|